Which has higher valuation & earnings, IFRX or KURA?

InflaRx has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 7,073.76 -$51.63M -$0.58 N/A Kura Oncology $67.48M 12.79 -$278.67M -$3.37 N/A

Is IFRX or KURA more profitable?

InflaRx has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. InflaRx's return on equity of -53.56% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Kura Oncology -384.30% -207.18% -45.17%

Does the media refer more to IFRX or KURA?

In the previous week, Kura Oncology had 7 more articles in the media than InflaRx. MarketBeat recorded 9 mentions for Kura Oncology and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.60 beat Kura Oncology's score of 0.25 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kura Oncology 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ODTX or IFRX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A InflaRx N/A -53.56% -43.02%

Does the media refer more to ODTX or IFRX?

In the previous week, Odyssey Therapeutics had 7 more articles in the media than InflaRx. MarketBeat recorded 9 mentions for Odyssey Therapeutics and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.60 beat Odyssey Therapeutics' score of 0.60 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, IFRX or ALMS?

InflaRx has higher earnings, but lower revenue than Alumis. InflaRx is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 7,073.76 -$51.63M -$0.58 N/A Alumis $24.05M 33.96 -$243.32M -$3.86 N/A

Is IFRX or ALMS more profitable?

InflaRx has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. InflaRx's return on equity of -53.56% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Alumis -5,933.46% -93.15% -74.50%

Does the media refer more to IFRX or ALMS?

In the previous week, Alumis had 8 more articles in the media than InflaRx. MarketBeat recorded 10 mentions for Alumis and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.60 beat Alumis' score of 0.57 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alumis 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IFRX or MLTX more profitable?

InflaRx's return on equity of -53.56% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% MoonLake Immunotherapeutics N/A -82.53% -58.17%

Is IFRX or JBIO more profitable?

Jade Biosciences' return on equity of -49.11% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Jade Biosciences N/A -49.11% -45.62%

InflaRx (IFRX) Competitors

$1.32 -0.12 (-8.33%)

Closing price 04:00 PM Eastern

Extended Trading

$1.34 +0.01 (+1.14%)

As of 07:48 PM Eastern

Compare

IFRX vs. KURA, ODTX, ALMS, MLTX, and JBIO

Should you buy InflaRx stock or one of its competitors? InflaRx's main competitors and comparable companies include Kura Oncology (KURA), Odyssey Therapeutics (ODTX), Alumis (ALMS), MoonLake Immunotherapeutics (MLTX), and Jade Biosciences (JBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does InflaRx compare to Kura Oncology?

InflaRx (NASDAQ:IFRX) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

InflaRx has a beta of 2.59, indicating that its stock price is 159% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

InflaRx has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. InflaRx's return on equity of -53.56% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Kura Oncology	-384.30%	-207.18%	-45.17%

InflaRx currently has a consensus target price of $7.43, indicating a potential upside of 415.87%. Kura Oncology has a consensus target price of $25.35, indicating a potential upside of 161.37%. Given InflaRx's higher possible upside, research analysts plainly believe InflaRx is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

InflaRx has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,073.76	-$51.63M	-$0.58	N/A
Kura Oncology	$67.48M	12.79	-$278.67M	-$3.37	N/A

42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Kura Oncology had 7 more articles in the media than InflaRx. MarketBeat recorded 9 mentions for Kura Oncology and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.60 beat Kura Oncology's score of 0.25 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Kura Oncology	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InflaRx beats Kura Oncology on 12 of the 16 factors compared between the two stocks.

How does InflaRx compare to Odyssey Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Odyssey Therapeutics presently has a consensus target price of $35.33, suggesting a potential upside of 101.10%. InflaRx has a consensus target price of $7.43, suggesting a potential upside of 415.87%. Given InflaRx's higher probable upside, analysts clearly believe InflaRx is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Odyssey Therapeutics has higher earnings, but lower revenue than InflaRx. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
InflaRx	$30K	7,073.76	-$51.63M	-$0.58	N/A

42.4% of InflaRx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Odyssey Therapeutics had 7 more articles in the media than InflaRx. MarketBeat recorded 9 mentions for Odyssey Therapeutics and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.60 beat Odyssey Therapeutics' score of 0.60 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Odyssey Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
InflaRx	N/A	-53.56%	-43.02%

Summary

InflaRx beats Odyssey Therapeutics on 6 of the 11 factors compared between the two stocks.

How does InflaRx compare to Alumis?

InflaRx (NASDAQ:IFRX) and Alumis (NASDAQ:ALMS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

InflaRx has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. InflaRx's return on equity of -53.56% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Alumis	-5,933.46%	-93.15%	-74.50%

42.4% of InflaRx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 33.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

InflaRx has higher earnings, but lower revenue than Alumis. InflaRx is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,073.76	-$51.63M	-$0.58	N/A
Alumis	$24.05M	33.96	-$243.32M	-$3.86	N/A

InflaRx has a beta of 2.59, suggesting that its stock price is 159% more volatile than the broader market. Comparatively, Alumis has a beta of -0.38, suggesting that its stock price is 138% less volatile than the broader market.

InflaRx currently has a consensus target price of $7.43, indicating a potential upside of 415.87%. Alumis has a consensus target price of $33.27, indicating a potential upside of 427.30%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Alumis had 8 more articles in the media than InflaRx. MarketBeat recorded 10 mentions for Alumis and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.60 beat Alumis' score of 0.57 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alumis	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InflaRx beats Alumis on 9 of the 15 factors compared between the two stocks.

How does InflaRx compare to MoonLake Immunotherapeutics?

InflaRx (NASDAQ:IFRX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, InflaRx had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for MoonLake Immunotherapeutics. InflaRx's average media sentiment score of 1.60 beat MoonLake Immunotherapeutics' score of 1.10 indicating that InflaRx is being referred to more favorably in the media.

Company	Overall Sentiment
InflaRx	Very Positive
MoonLake Immunotherapeutics	Positive

InflaRx has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,073.76	-$51.63M	-$0.58	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

InflaRx has a beta of 2.59, suggesting that its share price is 159% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

InflaRx's return on equity of -53.56% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

InflaRx presently has a consensus price target of $7.43, indicating a potential upside of 415.87%. MoonLake Immunotherapeutics has a consensus price target of $28.50, indicating a potential upside of 177.78%. Given InflaRx's stronger consensus rating and higher possible upside, equities research analysts plainly believe InflaRx is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
MoonLake Immunotherapeutics	3 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

InflaRx beats MoonLake Immunotherapeutics on 12 of the 14 factors compared between the two stocks.

How does InflaRx compare to Jade Biosciences?

InflaRx (NASDAQ:IFRX) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

InflaRx presently has a consensus target price of $7.43, suggesting a potential upside of 415.87%. Jade Biosciences has a consensus target price of $51.75, suggesting a potential upside of 276.09%. Given InflaRx's higher probable upside, equities analysts plainly believe InflaRx is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

In the previous week, InflaRx had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.82 beat InflaRx's score of 1.60 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
InflaRx	Very Positive
Jade Biosciences	Very Positive

42.4% of InflaRx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

InflaRx has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,073.76	-$51.63M	-$0.58	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

Jade Biosciences' return on equity of -49.11% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Jade Biosciences	N/A	-49.11%	-45.62%

InflaRx has a beta of 2.59, indicating that its stock price is 159% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Summary

InflaRx beats Jade Biosciences on 8 of the 14 factors compared between the two stocks.

Get InflaRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IFRX vs. The Competition

Export

Metric	InflaRx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$194.53M	$3.88B	$7.36B	$12.64B
Dividend Yield	N/A	3.66%	2.51%	19.61%
P/E Ratio	-2.28	12.49	274.15	24.85
Price / Sales	6,484.28	1,211.47	624.75	97.86
Price / Cash	N/A	118.95	76.19	51.56
Price / Book	2.03	15.94	10.29	5.86
Net Income	-$51.63M	-$22.69M	$3.50B	$380.67M
7 Day Performance	-17.50%	-8.67%	-5.37%	-4.97%
1 Month Performance	-35.29%	-14.11%	-8.55%	-6.95%
1 Year Performance	6.45%	0.66%	0.43%	-5.99%

InflaRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IFRX InflaRx	2.1034 of 5 stars	$1.32 -8.3%	$7.43 +462.8%	+15.2%	$194.53M	$30K	N/A	65	News Coverage Positive News Gap Up
KURA Kura Oncology	3.5738 of 5 stars	$10.49 -0.3%	$25.69 +145.0%	-5.7%	$933.20M	$77.23M	N/A	260	Analyst Forecast
ODTX Odyssey Therapeutics	3.216 of 5 stars	$19.34 +6.7%	$37.00 +91.3%	N/A	$929.46M	$99K	N/A	100
ALMS Alumis	3.9681 of 5 stars	$7.18 +2.9%	$33.27 +363.7%	+30.1%	$928.05M	$7.40M	N/A	239	Short Interest Increase
MLTX MoonLake Immunotherapeutics	3.1701 of 5 stars	$10.89 +2.9%	$28.50 +161.8%	+3.7%	$924.81M	N/A	N/A	130	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IFRX) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InflaRx (IFRX) Competitors

IFRX vs. KURA, ODTX, ALMS, MLTX, and JBIO

How does InflaRx compare to Kura Oncology?

Summary

How does InflaRx compare to Odyssey Therapeutics?

Summary

How does InflaRx compare to Alumis?

Summary

How does InflaRx compare to MoonLake Immunotherapeutics?

Summary

How does InflaRx compare to Jade Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InflaRx (IFRX) Competitors

IFRX vs. KURA, ODTX, ALMS, MLTX, and JBIO

How does InflaRx compare to Kura Oncology?

Which has more risk & volatility, IFRX or KURA?

Is IFRX or KURA more profitable?

Do analysts rate IFRX or KURA?

Which has higher valuation & earnings, IFRX or KURA?

Do insiders and institutionals believe in IFRX or KURA?

Does the media refer more to IFRX or KURA?

Summary

How does InflaRx compare to Odyssey Therapeutics?

Do analysts recommend ODTX or IFRX?

Which has higher valuation and earnings, ODTX or IFRX?

Do institutionals and insiders hold more shares of ODTX or IFRX?

Does the media refer more to ODTX or IFRX?

Is ODTX or IFRX more profitable?

Summary

How does InflaRx compare to Alumis?

Is IFRX or ALMS more profitable?

Do institutionals & insiders have more ownership in IFRX or ALMS?

Which has better valuation & earnings, IFRX or ALMS?

Which has more volatility and risk, IFRX or ALMS?

Do analysts prefer IFRX or ALMS?

Does the media refer more to IFRX or ALMS?

Summary

How does InflaRx compare to MoonLake Immunotherapeutics?

Do institutionals and insiders have more ownership in IFRX or MLTX?

Does the media refer more to IFRX or MLTX?

Which has higher earnings and valuation, IFRX or MLTX?

Which has more volatility & risk, IFRX or MLTX?

Is IFRX or MLTX more profitable?

Do analysts rate IFRX or MLTX?

Summary

How does InflaRx compare to Jade Biosciences?

Do analysts rate IFRX or JBIO?

Does the media favor IFRX or JBIO?

Do insiders and institutionals hold more shares of IFRX or JBIO?

Which has better earnings & valuation, IFRX or JBIO?

Is IFRX or JBIO more profitable?

Which has more risk and volatility, IFRX or JBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools